Barclays Down, Novartis Falls, WPP Disappoints | Stock Movers

Why It Matters

The mixed results signal heightened volatility for European financials, pharma, and advertising, prompting investors to scrutinize earnings quality and strategic pivots amid macro‑economic headwinds.

Key Takeaways

• Barclays Q1 trading unit lags US rivals, shares tumble.
• £200m impairment from specialist lender collapse hits Barclays profit.
• Novartis sales slump 42% on legacy drug Entresto, shares fall.
• Novartis aims growth via innovative cancer pill, guidance unchanged.
• WPP's Q1 sales steady but decline persists, shares dip.

Summary

The Bloomberg Stock Movers segment highlighted three European giants—Barclays, Novartis, and WPP—each grappling with earnings pressure in Q1 2024.

Barclays posted mixed results; equities trading rose 16% YoY, investment banking beat forecasts, but fixed‑income was flat and the bank recorded a £200 million impairment tied to the collapse of specialist lender MFS and a £100 million hit from a car‑loan saga. Novartis saw profit and revenue miss expectations, driven by a 42% plunge in sales of its legacy heart‑failure drug Entresto, though demand for its new breast‑cancer pill grew. WPP reported modest Q1 sales improvement over Q4, kept full‑year guidance, but its revenue trend remains downward, leaving the ad‑tech group still off the FTSE 100.

Louise Moon noted Barclays “struggled to capitalize on volatility” unlike US peers, while Novartis CEO’s push to shift from legacy medicines to innovative prescriptions was described as “a key test.” WPP’s turnaround narrative was tempered by analysts’ warning that consensus estimates won’t be raised despite steadier sales.

The earnings gaps underscore divergent regional dynamics: UK banks face heightened uncertainty, pharma firms confront product‑life‑cycle risks, and ad agencies wrestle with AI‑driven client churn. Investors may reassess exposure to these sectors as guidance remains unchanged but growth pathways appear uncertain.

Original Description

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Barclays traders struggled to capitalize on a volatile quarter with returns falling short of their US rivals.

- Novartis’s profit fell more than estimated and sales unexpectedly declined in the first quarter as some of the drugmaker’s best-selling medicines were hit hard by generic competition.

- WPP reported an organic sales decline of 6.7% in 1Q, higher than more pessimistic analyst forecasts.

See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Check out more episodes of Stock Movers: https://www.youtube.com/playlist?list=PLe4PRejZgr0NxhJreY_kjMBdW8cvmNauU

Visit us: https://www.bloomberg.com/podcasts

Follow Bloomberg Podcasts on Twitter: https://twitter.com/podcasts

Visit our other YouTube channels:

Bloomberg Television: https://www.youtube.com/@markets

Bloomberg Originals: https://www.youtube.com/bloomberg

Quicktake: https://www.youtube.com/@BloombergQuicktake

For coverage on news, markets and more: http://www.bloomberg.com/video

#Stocks #Markets #Finance #Investing #Podcast #Bloomberg

Barclays Down, Novartis Falls, WPP Disappoints